查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969878

全球疱疹感染疾病治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Herpes Infection Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计疱疹感染疾病治疗市场将从 2025 年的 47.7 亿美元成长到 2034 年的 86.1 亿美元，2026 年至 2034 年的复合年增长率为 6.77%。

随着单纯疱疹病毒（HSV）感染在全球范围内的增加，全球疱疹感染疾病治疗市场也持续成长。人们对性行为感染感染的认识不断提高，以及诊断技术的进步，促使更多患者寻求治疗。各国政府和卫生组织也积极进行宣传活动，以支持早期发现和医疗干预。

抗病毒药物仍然是主要的治疗选择，随着研究的不断深入，其疗效也不断提高。开发中国家医疗服务的扩展正在增加患者获得治疗的机会。此外，线上药局和远端医疗服务的普及也使疱疹感染疾病患者更容易获得咨询和药物治疗。

由于疫苗研发的进步和创新抗病毒疗法的开发，预计未来市场将持续成长。製药公司不断加大研发投入，以推出更有效、更永续的治疗方法。随着全球意识的提高和医疗基础设施的改善，疱疹感染疾病治疗市场预计将在未来几年稳步扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球疱疹感染疾病治疗市场：依治疗类型划分

  • 市场分析、洞察与预测
  • 抗病毒药物
  • 局部治疗
  • 疫苗
  • 支持性护理

第五章 全球疱疹感染疾病治疗市场：依给药途径划分

  • 市场分析、洞察与预测
  • 口服
  • 局部的
  • 静脉注射
  • 皮内给药

第六章 全球疱疹感染疾病治疗市场：依患者族群划分

  • 市场分析、洞察与预测
  • 成人
  • 青春期
  • 儿童

第七章 全球疱疹感染疾病治疗市场：依感染类型划分

  • 市场分析、洞察与预测
  • 生殖器疱疹
  • 口腔疱疹

第八章 全球疱疹感染疾病治疗市场：依治疗环境划分

  • 市场分析、洞察与预测
  • 医院
  • 门诊部
  • 居家照护

第九章 全球疱疹感染疾病治疗市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • AbbVie
    • Johnson & Johnson
    • Roche
    • Mylan
    • Bristol-Myers Squibb
    • Hikma Pharmaceuticals
    • Teva Pharmaceutical Industries
    • Sanofi
    • Novartis
    • AstraZeneca
    • Pfizer
    • Merck & Co
    • Gilead Sciences
    • GlaxoSmithKline
    • Amgen
简介目录
Product Code: VMR112110564

The Herpes Infection Treatment Market size is expected to reach USD 8.61 Billion in 2034 from USD 4.77 Billion (2025) growing at a CAGR of 6.77% during 2026-2034.

The Global Herpes Infection Treatment Market is growing due to the increasing prevalence of herpes simplex virus (HSV) infections worldwide. Rising awareness about sexually transmitted infections and better diagnostic methods are encouraging more patients to seek treatment. Governments and health organizations are also promoting awareness programs, which support early detection and medical intervention.

Antiviral medications remain the primary treatment option, and continuous research is improving their effectiveness. The expansion of healthcare services in developing countries is increasing patient access to treatment. In addition, the availability of online pharmacies and telemedicine services is making consultation and medication access easier for patients dealing with herpes infections.

In the future, the market is expected to grow with advancements in vaccine research and innovative antiviral therapies. Pharmaceutical companies are investing in research and development to introduce more effective and long-lasting treatment options. As awareness continues to increase and healthcare infrastructure improves globally, the herpes infection treatment market is projected to expand steadily in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Antiviral Medications
  • Topical Treatments
  • Vaccines
  • Supportive Therapies

By Administration Route

  • Oral
  • Topical
  • Intravenous
  • Intradermal

By Patient Demographics

  • Adults
  • Adolescents
  • Pediatric

By Infection Type

  • Genital Herpes
  • Oral Herpes

By Treatment Settings

  • Hospitals
  • Outpatient Clinics
  • Home Care

COMPANIES PROFILED

  • AbbVie, Johnson Johnson, Roche, Mylan, BristolMyers Squibb, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, Sanofi, Novartis, AstraZeneca, Pfizer, Merck Co, Gilead Sciences, GlaxoSmithKline, Amgen
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Antiviral Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Topical Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Supportive Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HERPES INFECTION TREATMENT MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Administration Route
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HERPES INFECTION TREATMENT MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Patient Demographics
  • 6.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adolescents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HERPES INFECTION TREATMENT MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Infection Type
  • 7.2. Genital Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Oral Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT SETTINGS 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Treatment Settings
  • 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Outpatient Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HERPES INFECTION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Treatment Type
    • 9.2.2 By Administration Route
    • 9.2.3 By Patient Demographics
    • 9.2.4 By Infection Type
    • 9.2.5 By Treatment Settings
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Treatment Type
    • 9.3.2 By Administration Route
    • 9.3.3 By Patient Demographics
    • 9.3.4 By Infection Type
    • 9.3.5 By Treatment Settings
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Treatment Type
    • 9.4.2 By Administration Route
    • 9.4.3 By Patient Demographics
    • 9.4.4 By Infection Type
    • 9.4.5 By Treatment Settings
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Treatment Type
    • 9.5.2 By Administration Route
    • 9.5.3 By Patient Demographics
    • 9.5.4 By Infection Type
    • 9.5.5 By Treatment Settings
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Treatment Type
    • 9.6.2 By Administration Route
    • 9.6.3 By Patient Demographics
    • 9.6.4 By Infection Type
    • 9.6.5 By Treatment Settings
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HERPES INFECTION TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 AbbVie
    • 11.2.2 Johnson & Johnson
    • 11.2.3 Roche
    • 11.2.4 Mylan
    • 11.2.5 Bristol-Myers Squibb
    • 11.2.6 Hikma Pharmaceuticals
    • 11.2.7 Teva Pharmaceutical Industries
    • 11.2.8 Sanofi
    • 11.2.9 Novartis
    • 11.2.10 AstraZeneca
    • 11.2.11 Pfizer
    • 11.2.12 Merck & Co
    • 11.2.13 Gilead Sciences
    • 11.2.14 GlaxoSmithKline
    • 11.2.15 Amgen